Come on, join the group and be part of GU community!

🎯 great discussion and proposals (new projects/clinical trials) in a urothelial cancer workshop! 😊 supported by a great Tom Powles #GUARDSymposium2024 OncoAlert GUARD Consortium Enrique Grande Álvaro Pinto Shilpa Gupta Yüksel Ürün Ashish M. Kamat, MD, MBBS UroTarget

Theragnostic is growing!! New tracers, new targets, new optionts for patients!! SEMNIM GUARD Consortium SAMN Hospital Universitario Reina Sofía IMIBIC #GUARDSymposium2024

Now with the one and only Tom Powles in the Advanced Bladder Cancer Workshop, speaking about the new therapeutic algorithm for this disease. #GUARDSymposium2024 OncoAlert

😊😊Many thanks Ashish M. Kamat, MD, MBBS for coming and excellent talk!! GUARD Consortium #GUARDSymposium2024

La colaboración entre Hispanoamericanos debe ser una realidad. Tenemos muchísimo en común y tenemos que aprovecharlo. Contar con GUARD Consortium para ello!!!! Muchísimas gracias a Ray Manneh Kopp Maite Bourlon y FLoscoMD por estar hoy con nosotros en el #GUARDSymposium2024 Haremos

Enrique Grande GUARD Consortium Ray Manneh Kopp Maite Bourlon FLoscoMD Que buen evento y que reconfortante que lo de grupos colaborativos si se haga realidad. Los que estamos en otros nichos de la oncología tenemos mucho que aprender de lo que han trabajado en urogenital, felicitaciones! Ray Manneh Kopp FLoscoMD Maite Bourlon Enrique Grande

🎯🎯 thanks Sabine D. Brookman-May for your update of the #Sunrise program and MoonRISE program!! Using a TAR-device for intravesical treament for NMIUC!! Great Job in J&J !! Johnson & Johnson GUARD Consortium #GUARDSymposium2024 OncoAlert European Association of Urology (EAU) Ashish M. Kamat, MD, MBBS Neeraj Agarwal, MD, FASCO Vadim Koshkin MD ASCO

Daniel Castellano GUARD Consortium Thank you for the invitation to be part of this excellent program. Honored to be part of the conversation!

Thank you Andrea Necchi for your continued support in our GUARD Consortium adventure in Spain, for your advices and your incredible talks. A giant of GU oncology at the #GUARDSymposium2024

⚠️Controversies, new approaches and latest novelties by Tom Powles and Andrea Necchi,🔝 doctors focused to improve BC management🌱🌱. Molecular carachterization and targeted therapies will help us to choose best treatment options!! Bernardo Herrera Imbroda Rocío Santos GUARD Consortium

Great talk related to MIBC by Andrea Necchi ctDNA is becoming important as useful tool in Bladder cancer clinical trial GUARD Consortium #GUARDSymposium2024

Terrific table addressing the challenges in perioperative MIBC setting at #GUARDSymposium2024 Two of the biggest stars ⭐️ gave light to this field Thanks Tom Powles and Andrea Necchi for believing ng here in Madrid today GUARD Consortium OncoAlert

No podía faltar la mejor representación nacional en el #GUARDSymposium2024 La Dra. MJosé Juan acaba de dejar el nivel de la Oncología en 🇪🇸 España al mayor nivel. Orgullosos de ti!!!🤫 OncoAlert GUARD Consortium

Javier Puente GUARD Consortium Thank you and the entire team for inviting me and for such a warm hospitality😍 Daniel Castellano Enrique Grande Guillermo de Velasco #GUARDSymposium2024

😊 great talk MJosé Juan and Vadim Koshkin MD about sequencing therapies and reverse mechanism of resistance for mUC!!!🔥#GUARDSymposium2024 OncoAlert GUARD Consortium Enrique Grande Elena Sevillano M.D. PhD

💫🌟Resultados y Mensajes Principales de la Revisión Completa sobre Terapias Dirigidas para Carcinoma Urotelial Avanzado🌟💫 OncoAlert OncoReporte 🟠Cáncer de Vejiga (BC): 10º más común a nivel mundial. El carcinoma urotelial avanzado (aUC) tiene malos resultados y tasas de

Dr. Guerrero-Ramos on the evolving treatment landscape in NMIBC urologytimes.com/view/dr-guerre… vía @urologytimes Shahrokh F. Shariat Antoni Vilaseca Ashish M. Kamat, MD, MBBS Sia Daneshmand, M.D. Morgan Roupret Paolo Gontero European Urology Oncology UroSoMe GUO-AEU European Association of Urology (EAU) Óscar Rodríguez Faba Mario AlvarezMaestro bibliotecah12o GUARD Consortium

🌟📢 Nivolumab/Tivozanib Fails to Improve PFS in Advanced RCC🌟 OncoAlert OncLive.com 🔹 TiNivo-2 Study: Nivolumab + tivozanib did not improve progression-free survival (PFS) in advanced RCC after prior immune checkpoint inhibitors. 🔹 Control Arm: Tivozanib monotherapy showed

Join us next August 29th from 18:30 to 19:30, to discuss about adverse events and toxicity management in patients with metastatic prostate cancer. European Association of Urology (EAU) European School of Urology (EAU ESU) Giorgio Gandaglia webinars.uroweb.org/EAU/webinars